

What's
new?


Feature Product: KL-6 ELISA Kit

The significance of KL-6 as a predictor or biomarker in lung cancer and connective tissue diseases with interstitial lung diseases.

◆Introduction

It has been reported that interstitial lung diseases (ILDs) are associated with Lung cancer and connective tissue diseases (CTDs) such as rheumatoid arthritis (RA), polymyositis / dermatomyositis (PM/DM) and systemic sclerosis (SSc). In particular, the morbidity and mortality has increased due to a lack of effective therapies for these IDLs-associated diseases. The problem needs to identify it in the early stages of these diseases. Therefore, it is expected that KL-6 could be potentially useful as a predictor or biomarker in the near future.

◆Principle



EIDIA Co., Ltd.

Assay Characteristics

- Sandwich Enzyme Immunoassay
- Assay range: 201~4020 U/mL
- Sample type: Human serum
- Monoclonal antibodies are used.
- Superior reproducibility and linearity

Key Words: KL-6, lung cancer, acute exacerbation, connective tissue diseases, polymyositis/dermatomyositis, rheumatoid arthritis, systemic sclerosis, interstitial lung diseases

References

●Lee YS, Kim HC, Lee BY, Lee CK, Kim MY, Jang SJ, Lee HS, Moon J, Colby TV, Kim DS.

The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):216-223.

●Fathi M, Barbasso Helmers S, Lundberg IE.

KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.

J Intern Med. 2012 Jun;271(6):589-97. doi: 10.1111/j.1365-2796.2011.02459.x.

●Masataka Kuwana, Yuichiro Shirai and Tsutomu Takeuchi

Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.

The Journal of Rheumatology 2016; 43:10; doi:10.3899/jrheum.160339